Not a buy recommendation
*Ind-Swift Labs-Why will it turn out to be a Real Multibagger ?*
One of the largest standalone provider of Active Pharmaceutical Ingredients (“API”) development and manufacturing services in India
Highly attractive and diversified portfolio of 32 products across 18 therapeutic categories
Specializes in complex chemistry APIs for fast growing therapeutic segments, with a focus on anti-infectives
*Manufactures API for products sold in 70+countries including some of the largest regulated and “pharmerging” markets*
Fully backward integrated API manufacturing capabilities providing cost competitiveness
State-of-the-art R&D centre in Mohali(Punjab) spread over 2 acres
Recently started CRAMS (CRO) services for API in pharma and non-pharma sector
Broad and well Diversified revenue base which provides a visibility of future revenues
Large, Attractive and Growing API Market which provides good visibility for future
Long standing relationship with key customers provides sticky and predictable revenue base. Key clients include big names like *Cipla, Cadila, Aurobindo Pharma* etc
High quality manufacturing facilities with an impressive track record with all major regulatory authorities
One of the largest API manufacturers globally for Clarithromycin for the last 15+ years. Supplying Clarithromycin to 127 customers in 50 countries
One of the leading suppliers globally of APIs for Fexofenadine and Atorvastatin
*26 cGMP compliant manufacturing blocks spread over 650,000 sq. ft. in two locations*
643KL reactor and 695MT for bulk drugs/API
5.5 MW captive power plant
Capacity utilization of plant stands at 67% (Dera Bassi) and 64% (Jammu). *Under new management, utilisation can go upto 95% easily*
Capex spend of 550cr in last 10 years
*Dedicated facility with eight synthetic labs over 40,000 sq. ft research area*
Inhouse team for assessment and guidance on Intellectual Property(IP) related matters
*Ownership of new IP and its rights lies with the Company; for CRAMS in consultation with client*